Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Amrita Krishnan et al.|New England Journal of Medicine|2022Cited by 1.2k
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z. Usmani, Amrita Krishnan, Alfred L. Garfall et al.|The Lancet|2021Cited by 321
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortés‐Selva, Raluca Verona, Tatiana Perova et al.|Blood|2024Cited by 60
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)Alfred L. Garfall, Amrita Krishnan, Saad Z. Usmani et al.|Blood|2020Cited by 60
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Blood Advances|2022Cited by 52